Antibiotic lung penetration study launches in china

NCT ID NCT07124468

First seen Nov 01, 2025 · Last updated Apr 30, 2026 · Updated 22 times

Summary

This early-stage trial is testing how much of the antibiotic meropenem-pralubactam gets into the lungs of 16 healthy adults in China. Participants will receive four doses of the drug intravenously, and researchers will measure its levels in blood and lung fluids. The study does not aim to treat any disease, but to gather important information for future infection treatments.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The First Affiliated Hospital of Fujian Medical University

    RECRUITING

    Fuzhou, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.